Filtered By:
Condition: Bleeding
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 447 results found since Jan 2013.

Impact of right and left ventricular systolic dysfunction on perioperative outcome and long ‐term survival after transcatheter aortic valve replacement
ConclusionsPeri‐operative mortality and risk of stroke after TAVR are not adversely affected by preexisting RV or LV dysfunction. Long‐term survival is impaired in patients with RVSD. RVSD but not LVSD is an independent risk factor for late mortality. TAVR should be the preferred therapy for patients with RVSD and LVSD, especially when patient is suitable for TF.
Source: Journal of Interventional Cardiology - April 25, 2017 Category: Cardiology Authors: Daniel P. Griese, Sebastian Kerber, Sebastian Barth, Anno Diegeler, J örg Babin‐Ebell, Wilko Reents Tags: ORIGINAL INVESTIGATION Source Type: research

Abstract P438: Cardio-Renal Anemia Syndrome in acute heart failure patients: An Observational data from “Gulf-CARE” Heart Failure Registry Session Title: Chronic Kidney Disease
Conclusions: In the setting of acute heart failure in CRAS patients LV function has no significant role in the incidence of in-hospital stroke, major bleeding and death.
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Mohammed Al Jarallah, Rajesh Rajan, Ahmed R. Al-Saber, Raja Dashti, Bassam Bulbanat, Mustafa Ridha, Khadhim Sulaiman, Prashanth Panduranga, Alawi Alshekh-Ali, Khalid Al Habib, Jassim Al Suwaidi, Wael Al Mahmeed, Hussam Al Faleh, Abdelfatah Elasfar, Ahmed Tags: Poster Abstract Presentations Source Type: research

Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction
ConclusionIn patients with ESRD and AMI, ticagrelor resulted in numerically fewer but statistically nonsignificant rates of in-hospital and 1-year cardiovascular events with no significant increase in bleeding events compared with clopidogrel.
Source: American Journal of Cardiovascular Drugs - February 12, 2019 Category: Cardiology Source Type: research

Anticoagulation in Patients with Advanced Chronic Kidney Disease: Walking the Fine Line between Benefit and Harm
Publication date: Available online 11 July 2019Source: Canadian Journal of CardiologyAuthor(s): Januvi Jegatheswaran, Gregory L. Hundemer, David Massicotte-Azarniouch, Manish M. SoodAbstractChronic kidney disease affects over 3 million Canadians and is highly associated with cardiovascular diseases that require anticoagulation, such as atrial fibrillation and venous thromboembolism. Patients with chronic kidney disease are at a problematic crossroads; they are at high risk of both thrombotic conditions requiring anticoagulation and bleeding complications due to anticoagulation. The limited high-quality clinical evidence to...
Source: Canadian Journal of Cardiology - July 12, 2019 Category: Cardiology Source Type: research

Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Conclusion: In early-stage CKD, NOACs had a benefit-risk profile superior to that of VKAs. For advanced CKD or ESKD, there was insufficient evidence to establish benefits or harms of VKAs or NOACs. Primary Funding Source: None. (PROSPERO: CRD42017079709). PMID: 31307056 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 15, 2019 Category: Internal Medicine Authors: Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, Jardine MJ, Sood MM, Garg AX, Palmer SC, Mark PB, Wheeler DC, Jha V, Freedman B, Johnson DW, Perkovic V, Badve SV Tags: Ann Intern Med Source Type: research

Minimally ‐invasive parasternal aortic valve replacement–A slow learning curve towards improved outcomes
ConclusionsParasternal minimally ‐invasive aortic valve replacement is a feasible technique associated with a slow learning curve but the potential to achieve improved outcomes. Considering the transcatheter alternatives, the relative risk reduction may be worth investigating in future trials.
Source: Journal of Cardiac Surgery - January 14, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Sophio Tkebuchava, Gloria F ärber, Christoph Sponholz, Frank Fuchs, Petra Heinisch, Michael Bauer, Torsten Doenst Tags: ORIGINAL ARTICLE Source Type: research

Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure
AbstractPurpose of ReviewThe purpose of this review is to examine the safety and effectiveness of direct oral anticoagulants and provide recommendations for the treatment of venous thromboembolism and atrial fibrillation in obese patients, elderly patients, and patients with chronic kidney disease.Recent FindingsMultiple retrospective cohort studies have shown no difference in bleeding, stroke, or venous thromboembolism outcomes between DOACs and warfarin in patients who are obese, elderly, or those with chronic kidney disease or on dialysis. Some studies have shown that DOACs have a lower bleeding risk than warfarin in th...
Source: Current Cardiology Reports - March 2, 2021 Category: Cardiology Source Type: research

Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure
CONCLUSIONS: Prasugrel or ticagrelor does not seem to be associated with significant benefits compared with clopidogrel in patients with kidney failure treated with drug-eluting stents.PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_04_02_CJN12120720.mp3.PMID:33811128 | DOI:10.2215/CJN.12120720
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 3, 2021 Category: Urology & Nephrology Authors: Thomas A Mavrakanas Omer Kamal David M Charytan Source Type: research

Antiplatelet agents for chronic kidney disease
CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.PMID:35224730 | DOI:10.1002/14651858.CD008834.pub4
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Valeria M Saglimbene Marinella Ruospo Mona Razavian Jonathan C Craig Meg J Jardine Angela C Webster Giovanni Fm Strippoli Source Type: research

Po-701-04 outcomes of left atrial appendage closure in patients with atrial fibrillation and end-stage renal disease on dialysis
Oral anticoagulation (OAC) therapy is the mainstay of treatment for stroke-risk reduction in patients with atrial fibrillation (AF). However, OAC use in patients with end-stage renal disease (ESRD) on dialysis is associated with a significantly increased risk of bleeding and an uncertain benefit in stroke reduction. In these patients, left atrial appendage closure (LAAC) could be alternative.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jorge Romero, Juan C. Diaz, Sutopa Purkayastha, Jorge Marin, Julian M. Aristizabal, Daniel Rodriguez, Isabella Alviz, Mauricio Duque, Mohamed Gabr, Maria Gamero, Jose Matias, Marta Lorente-Ros, Luis Ernesto Cerna, Dhanunjaya R. Lakkireddy, Rishi Charate, Source Type: research

Hybrid type II and frozen elephant trunk in acute Stanford type A aortic dissections
Conclusion. Hybrid II should be considered in favour of FET technique in acute Stanford type A dissection patients who are at higher risk due to age and comorbidities.PMID:35546567 | DOI:10.1080/14017431.2022.2074095
Source: Scandinavian Cardiovascular Journal - May 13, 2022 Category: Cardiology Authors: Jai Sule Cher Rui Chua Caven Teo Andrew Choong Faizus Sazzad Theo Kofidis Vitaly Sorokin Source Type: research